Print

UBI HIV-1MN octameric - Australia study

Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection. u

Trial Details:

I/II Completed
UBI November 01, 1993
UBI HIV-1 Peptide Immunogen, Multivalent
UBI HIV-1 Peptide Immunogen, Multivalent Protein
Australia 24